Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Guidance II -- Ignore unavailable to you. Want to Upgrade?

To: DebtBomb who wrote (861)	3/20/2002 10:28:07 PM
From: 2MAR$	Respond to of 2077

Mar 14 2002 8:43 AM In Play ViroPharma initiated with Sell rating at Fulcrum (VPHM) 17.50: Fulcrum initiates VPHM with a SELL rating; firm believes that the March 19 Antiviral Drugs Advisory Committee meeting for Picovir will result in a recommendation against approval to the FDA, which could prompt a selloff of the shares down to as low as $7.50; firm is also concerned about what it views as a very weak co-promotion partnership as well as a director's recent stock sales and hedging arrangement. Might have to pay more attention next time to these guys when they put the "Sell" on a biotech .. ;-)